19 active not recruiting. 19 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Active not recruiting 19 |
| Phase 3 | 2 | Active not recruiting 2 |
| Phase 1 | 1 | Active not recruiting 1 |
Follow Respiratory Hypersensitivity: new trials by email Literature Review of Respiratory Hypersensitivity trials Research Report on Respiratory Hypersensitivity
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR) Verekitug, Placebo - Severe Asthma | Phase 2 | Active not recruiting | Upstream Bio Inc. | 396 | 2025-05-21 | 2026-05-14 |
| Study of MG-ZG122 Humanized Monoclonal Antibody in Asthma Subjects MG-ZG122 Humanized Monoclonal Antibody Injection, Placebo - Bronchial Asthma | Phase 2 | Active not recruiting | Shanghai Mabgeek Biotech.Co.Ltd | 160 | 2025-05-11 | 2025-07-08 |
| A Dose Finding Study With an Anti-TSLP Antibody (GSK5784283) in Adults Aged 18 to 75 Years of Age With Uncontrolled Asthma GSK5784283, Placebo - Asthma | Phase 2 | Active not recruiting | GlaxoSmithKline | 307 | 2025-02-10 | 2026-10-26 |
| A Phase IIb Study of 610 in Participants With Severe Eosinophilic Asthma 610, Placebo - Asthma | Phase 2 | Active not recruiting | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. | 225 | 2024-12-20 | 2026-01-29 |
| Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma Lunsekimig, Short-Acting Beta Agonists (SABA), Placebo - Asthma | Phase 2 | Active not recruiting | Sanofi | 556 | 2024-11-07 | 2026-09-22 |
| Oral Intake of Mg in Controlled Asthmatic Patients Magnesium, ICS+LABA - Bronchial Asthma | Phase 2 / Phase 3 | Active not recruiting | Zagazig University | 166 | 2024-11-02 | 2025-08-14 |
| A Study to Evaluate Solriktug in Adult Participants With Asthma NSI-8226, Placebo - Asthma | Phase 2 | Active not recruiting | Uniquity One (UNI) | 145 | 2024-07-26 | 2026-08-11 |
| A Study Evaluating the Safety and Efficacy of Inhaled AP01 in Participants With Progressive Pulmonary Fibrosis AP01, Placebo - Pulmonary Fibrosis, Progressive Pulmonary Fibrosis | Phase 2 | Active not recruiting | Avalyn Pharma Inc. | 398 | 2024-04-03 | 2026-10-16 |
| A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). GR1802 injection, Placebo - Allergic Rhinitis | Phase 2 | Active not recruiting | Genrix (Shanghai) Biopharmaceutical Co., Ltd. | 240 | 2024-03-24 | 2025-04-25 |
| Tezepelumab in Allergic Rhinitis and Asthma Study (TEZARS) Tezepelumab - Asthma With Allergic Rhinitis | Phase 2 | Active not recruiting | Dr. Anne Ellis | 19 | 2024-01-29 | 2026-01-20 |
| Mechanisms of Benefit of IL4RA Inhibition in Aspirin-Exacerbated Respiratory Disease Dupilumab - Nasal Polyps, Asthma, Aspirin-Induced | Phase 2 | Active not recruiting | Brigham and Women's Hospital | 17 | 2023-08-01 | 2026-08-13 |
| A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Inadequately Controlled Moderate to Severe Asthma povorcitinib, placebo, ICS-LABA - Moderate to Severe Asthma | Phase 2 | Active not recruiting | Incyte Corporation | 247 | 2023-07-11 | 2026-07-07 |
| Dupilumab Effects Against Aeroallergen Challenge Dupilumab, House Dust Mites (HDM), Placebo - Asthma, Allergic | Phase 2 | Active not recruiting | The University of Texas Health Science Center at San Antonio | 96 | 2023-03-29 | 2026-08-11 |
| Glucagon-Like Peptide-1 Receptor Agonist in the Treatment of Adult, Obesity-related, Symptomatic Asthma (GATA-3) Semaglutide Pen Injector 2.4mg weekly, Placebo - Asthma | Phase 2 | Active not recruiting | Vanderbilt University Medical Center | 100 | 2022-10-11 | 2026-10-01 |
| Prevention of Asthma Exacerbations Using Dupilumab in Urban Children and Adolescents Dupilumab, Placebo - Asthma | Phase 2 | Active not recruiting | National Institute of Allergy and Infectious Diseases (NIAID) | 240 | 2022-05-04 | 2026-01-20 |
| Symptom-driven ICS/LABA Therapy for Patients With Asthma Non-adherent to Daily Maintenance Inhalers Adherence to symptom driven budesonide/formoterol as compared to adherence to maintenance ICS and symptom-driven SABA - Asthma, Nonadherence, Medication | Phase 1 / Phase 2 | Active not recruiting | Washington University School of Medicine | 60 | 2021-12-16 | 2026-08-19 |
| Deflazacort Vs. Prednisolone in Acute-stage ABPA Deflazacort, Prednisolone - Allergic Bronchopulmonary Aspergillosis | Phase 2 / Phase 3 | Active not recruiting | Post Graduate Institute of Medical Education and Research, Chandigarh | 150 | 2020-01-15 | 2025-02-28 |
| Preventing Asthma in High Risk Kids Omalizumab, Placebo - Asthma | Phase 2 | Active not recruiting | Boston Children's Hospital | 200 | 2018-11-27 | 2025-12-04 |
| Benralizumab in the Treatment of Eosinophilic Granulomatosis With Polyangiitis (EGPA) Study Benralizumab - Asthma | Phase 2 | Active not recruiting | National Jewish Health | 10 | 2017-04-15 | 2021-03-08 |
Asthma (15) · Rhinitis, Allergic (2) · Alveolitis, Extrinsic Allergic (1) · Aspergillosis, Allergic Bronchopulmonary (1) · Asthma, Aspirin-Induced (1) · Bronchial Diseases (1) · Dust Mite Allergy (1) · Hypersensitivity (1) · Lung Diseases (1) · Lung Diseases, Interstitial (1) · Medication Adherence (1) · Nasal Polyps (1) · Obesity (1) · Pulmonary Fibrosis (1) · Respiratory Tract Diseases (1)
Hypersensitivity, Immediate (19) · Immune System Diseases (19) · Hypersensitivity (18) · Respiratory Tract Diseases (18) · Bronchial Diseases (15) · Lung Diseases (15) · Lung Diseases, Obstructive (15) · Nose Diseases (4) · Otorhinolaryngologic Diseases (4) · Pathological Conditions, Signs and Symptoms (3) · Rhinitis (3) · Aspergillosis (1) · Asthma (1) · Bacterial Infections and Mycoses (1)
dupilumab (3) · Albuterol (1) · Antigens, Dermatophagoides (1) · Budesonide (1) · Budesonide, Formoterol Fumarate Drug Combination (1) · Fluticasone-Salmeterol Drug Combination (1) · Formoterol Fumarate (1) · Magnesium (1) · Omalizumab (1) · Prednisolone (1) · benralizumab (1) · deflazacort (1) · semaglutide (1) · tezepelumab (1)
Avalyn Pharma Inc. (1) · Boston Children's Hospital (1) · Brigham and Women's Hospital (1) · Dr. Anne Ellis (1) · Genrix (Shanghai) Biopharmaceutical Co., Ltd. (1) · GlaxoSmithKline (1) · Incyte Corporation (1) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · National Jewish Health (1) · Post Graduate Institute of Medical Education and Research, Chandigarh (1) · Sanofi (1) · Shanghai Mabgeek Biotech.Co.Ltd (1) · Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd. (1) · The University of Texas Health Science Center at San Antonio (1) · Uniquity One (UNI) (1)
United States (13) · Canada (6) · Germany (5) · Spain (5) · Argentina (4) · China (4) · Japan (4) · Poland (4) · United Kingdom (4) · Italy (3) · Belgium (2) · Bulgaria (2) · Chile (2) · Czechia (2) · France (2)
Andrew W Lee, MD (1) · Anne K Ellis, MD (1) · Daniel J. Jackson, M.D. (1) · James G Krings, MD MSc (1) · Justin Salciccioli, MD (1) · Katherine Cahill, MD (1) · Michael Wechsler, MD (1) · Min Zhang, Doctor (1) · Sunil K Ahuja, MD (1) · Tanya M Laidlaw, MD (1) · Wanda Phipatanakul, MD, MS (1) · Zheng Liu, PHD (1)
PMID 30954166, PMID 32453217, PMID 33242697, PMID 36471430, PMID 36948586, PMID 41448793, PMID 41567689
KL2TR002346 (1), U01AI155299 (1), U01AI158460 (1), U01AI179563 (1), U19AI095219 (1), UL1TR002345 (1)